Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases

Annals of the New York Academy of Sciences

Volumn 1069, Issue , 2006, Pages 62-76

  Calcagni, Emanuele ^a   Elenkov, Ilia ^a  

^a University of Study of Roma San Raffaele   (Italy)

Author keywords

Autoimmunity; Cytokines; Innate immunity; Stress; T helper 1 and T helper 2 cells

Indexed keywords

C REACTIVE PROTEIN; CATECHOLAMINE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GAMMA INTERFERON; GLUCOCORTICOID; HISTAMINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; AUTOIMMUNITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; FEEDBACK SYSTEM; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFECTION; INFLAMMATION; MAJOR DEPRESSION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PREGNANCY; PUERPERIUM; RHEUMATOID ARTHRITIS; STRESS; TH1 CELL; TH2 CELL;

EID: 33745616076     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1351.006     Document Type: Conference Paper

References (83)

1. ELENKOV, I.J. & G.P. CHROUSOS. 1999. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 10: 359-368.
2. ELENKOV, I.J., D.A. PAPANICOLAOU, R.L. WILDER & G.P. CHROUSOS. 1996. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc. Assoc. Am. Physicians 108: 374-381.
3. PANINA-BORDIGNON, P., D. MAZZEO, P.D. LUCIA, et al. 1997. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100: 1513-1519.
4. HASKO, G., C. SZABO, Z.H. NEMETH, et al. 1998. Stimulation of beta-adrenoceptors inhibits endotoxin-induced IL-12 production in normal and IL-10 deficient mice. J. Neuroimmunol. 88: 57-61.
5. BLOTTA, M.H., R.H. DEKRUYFF & D.T. UMETSU. 1997. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J. Immunol. 158: 5589-5595.
6. DEKRUYFF, R.H., Y. FANG & D.T. UMETSU. 1998. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J. Immunol. 160: 2231-2237.
7. WU, C.Y., K. WANG, J.F. MCDYER & R.A. SEDER. 1998. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161: 2723-2730.
8. RAMIERZ, F., D.J. FOWELL, M. PUKLAVEC, et al. 1996. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J. Immunol. 156: 2406-2412.
9. VAN DER POLL, T., A.E. BARBER, S.M. COYLE & S.F. LOWRY. 1996. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia - a clinical research center study. J. Clin. Endocrinol. Metab. 81: 3604-3606.
10. HETIER, E., J. AYALA, A. BOUSSEAU & A. PROCHIANTZ. 1991. Modulation of interleukin-1 and tumor necrosis factor expression by beta-adrenergic agonists in mouse ameboid microglial cells. Exp. Brain Res. 86: 407-413.
11. SEVERN, A., N.T. RAPSON, C.A. HUNTER & F.Y. LIEW. 1992. Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J. Immunol. 148: 3441-3445.
12. NAKAMURA, A., E.J. JOHNS, A. IMAIZUMI, et al. 1998. Regulation of tumour necrosis factor and interleukin-6 gene transcription by beta2-adrenoceptor in the rat astrocytes. J. Neuroimmunol. 88: 144-153.
13. KOFF, W.C., A.V. FANN, M.A. DUNEGAN & L.B. LACHMAN. 1986. Catecholamine-induced suppression of interleukin-1 production. Lymphokine Res. 5: 239-247.
14. VAN DER POLL, T. & S.F. LOWRY. 1997. Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10 Am. J. Physiol. 273: R1885-R1890.
15. SANDERS, V.M., R.A. BAKER, D.S. RAMER-QUINN, et al. 1997. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J. Immunol. 158: 4200-4210.
16. BORGER, P., Y. HOEKSTRA, M.T. ESSELINK, et al. 1998. Beta-adrenoceptor- mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Am. J. Respir. Cell Mol. Biol. 19: 400-407.
17. VAN DER POLL, T., S.M. COYLE, K. BARBOSA, et al. 1996. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J. Clin. Invest. 97: 713-719.
18. NORRIS, J.G. & E.N. BENVENISTE. 1993. Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J. Neuroimmunol. 45: 137-145.
19. MAIMONE, D., C. CIONI, S. ROSA, et al. 1993. Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J. Neuroimmunol. 47: 73-81.
20. NASEER, T., E.M. MINSHALL, D.Y. LEUNG, et al. 1997. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am. J. Respir. Crit. Care Med. 155: 845-851.
21. BENTLEY, A.M., Q. HAMID, D.S. ROBINSON, et al. 1996. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am. J. Respir. Crit. Care Med. 153: 551-556.
22. BRADDING, P., I.H. FEATHER, S. WILSON, et al. 1995. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am. J. Respir. Crit. Care Med. 151: 1900-1906.
23. BATUMAN, O.A., A. FERRERO, C. CUPP, et al. 1995. Differential regulation of transforming growth factor beta-1 gene expression by glucocorticoids in human T and glial cells. J. Immunol. 155: 4397-4405.
24. BROUG-HOLUB, E. & G. KRAAL. 1996. Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin. Exp. Immunol. 104: 332-336.
25. SPENGLER, R.N., R.M. ALLEN, D.G. REMICK, et al. 1990. Stimulation of α-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J. Immunol. 145: 1430-1434.
26. LETULZO, Y., R. SHENKAR, D. KANEKO, et al. 1997. Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J. Clin. Invest. 99: 1516-1524.
27. BAKER, A.J. & R.W. FULLER. 1995. Loss of response to beta-adrenoceptor agonists during the maturation of human monocytes to macrophages in vitro. J. Leukoc. Biol. 57: 395-400.
28. KAVELAARS, A., D.P. VAN, J. ZIJLSTRA & C.J. HEIJNEN. 1997. Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. J. Neuroimmunol. 77: 211-216.
29. LINDEN, A. 1996. Increased interleukin-8 release by beta-adrenoceptor activation in human transformed bronchial epithelial cells. Br. J. Pharmacol. 119: 402-406.
30. ENGSTAD, C.S., T. LUND & B. OSTERUD. 1999. Epinephrine promotes EL-8 production in human leukocytes via an effect on platelets. Thromb. Haemost. 81: 139-145.
31. KAPLANSKI, G., R. PORAT, K. AIURA, et al. 1993. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 81: 2492-2495.
32. MOHAMED-ALI, V., L. FLOWER, J. SETHI, et al. 2001. beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 86: 5864-5869.
33. VICENNATI, V., A. VOTTERO, C. FRIEDMAN & D.A. PAPANICOLAOU. 2002. Hormonal regulation of interleukin-6 production in human adipocytes. Int. J. Obes. Relat. Metab. Disord. 26: 905-911.
34. BAUMANN, H. & J. GAULDIE. 1994. The acute phase response. Immunol. Today 15: 74-80.
35. MURRAY, D.R., S.D. PRABHU & B. CHANDRASEKAR. 2000. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101: 2338-2341.
36. KARALIS, K., H. SANO, J. REDWINE, et al. 1991. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254: 421-423.
37. ELENKOV, I.J., E.L. WEBSTER, D.J. TORPY & G.P. CHROUSOS. 1999. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann. N. Y. Acad. Sci. 876: 1-11.
38. KOHNO, M., Y. KAWAHITO, Y. TSUBOUCHI, et al. 2001. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J. Clin. Endocrinol. Metab 86: 4344-4352.
39. UDELSMAN, R., W.T. GALLUCCI, J. BACHER, et al. 1986. Hemodynamic effects of corticotropin releasing hormone in the anesthetized cynomolgus monkey. Peptides 7: 465-471.
40. THEOHARIDES, T.C., L.K. SINGH, W. BOUCHER, et al. 1998. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139: 403-413.
41. FOREMAN, J.C. 1987. Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int. Arch. Allergy Appl. Immunol. 82: 366-371.
42. CHURCH, M.K., M.A. LOWMAN, C. ROBINSON, et al. 1989. Interaction of neuropeptides with human mast cells. Int. Arch. Allergy Appl. Immunol. 88: 70-78.
43. THEOHARIDES, T.C., C. SPANOS, X. PANG, et al. 1995. Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 136: 5745-5750.
44. LERNER, B.H. 1996. Can stress cause disease? Revisiting the tuberculosis research of Thomas Holmes, 1949-1961. Ann. Intern. Med. 124: 673-680.
45. LEVENSTEIN, S., S. ACKERMAN, J.K. KIECOLT-GLASER & A. DUBOIS. 1999. Stress and peptic ulcer disease. JAMA 281: 10-11.
46. ELENKOV, I.J. & E.S. VIZI. 1991. Presynaptic modulation of release of noradrenaline from the sympathetic nerve terminals in the rat spleen. Neuropharmacology 30: 1319-1324.
47. VIZI, E.S., E. ORSO, O.N. OSIPENKO, et al. 1995. Neurochemical, electrophysiological and immunocytochemical evidence for a noradrenergic link between the sympathetic nervous system and thymocytes. Neuroscience 68: 1263-1276.
48. COLE, S.W., Y.D. KORIN, J.L. FAHEY & J.A. ZACK. 1998. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J. Immunol. 161: 610-616.
49. CLERICI, M., M. BEVILACQUA, T. VAGO, et al. 1994. An immunoendocrinological hypothesis of HIV infection [see comments]. Lancet 343: 1552-1553.
50. KINO, T., A. GRAGEROV, J.B. KOPP, et al. 1999. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor (in process citation). J. Exp. Med. 189:51-62.
51. SEGAL, B.M., B.K. DWYER & E.M. SHEVACH. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187: 537-546.
52. WILDER, R.L. 1995. Neuroendocrine-immune system interactions and autoimmunity. Annu. Rev. Immunol. 13: 307-338.
53. WILDER, R.L. & I.J. ELENKOV. 1999. Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Ann. N. Y. Acad. Sci. 876: 14-31.
54. STRAUB, R.H. & M. CUTOLO. 2001. Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 44: 493-507.
55. KARASZEWSKI, J.W., A.T. REDER, R. MASELLI, et al. 1990. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann. Neurol. 27: 366-372.
56. ARNASON, B.G., M. BROWN, R. MASELLI, et al. 1988. Blood lymphocyte beta-adrenergic receptors in multiple sclerosis. Ann. N. Y. Acad. Sci. 540: 585-588.
57. KARASZEWSKI, J.W., A.T. REDER, B. ANLAR & G.W. ARNASON. 1993. Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J. Neuroimmunol. 43: 1-7.
58. CHELMICKA-SCHORR, E., M.N. KWASNIEWSKI, B.E. THOMAS & B.G. ARNASON. 1989. The beta-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol. 25: 203-207.
59. WIEGMANN, K., S. MUTHYALA, D.H. KIM, et al. 1995. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats. J. Neuroimmunol. 56: 201-206.
60. LORTON, D., D. BELLINGER, M. DUCLOS, et al. 1996. Application of 6-hydroxydopamine into the fatpads surrounding the draining lymph nodes exacerbates adjuvant-induced arthritis. J. Neuroimmunol. 64: 103-113.
61. FELTEN, D.L., S.Y FELTEN, D.L. BELLINGER & D. LORTON. 1992. Noradrenergic and peptidergic innervation of secondary lymphoid organs: role in experimental rheumatoid arthritis. Eur. J. Clin. Invest. 22(Suppl 1): 37-41.
62. MALFAIT, A.M., A.S. MALIK, L. MARINOVA-MUTAFCHIEVA, et al. 1999. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J. Immunol. 162: 6278-6283.
63. GEENEN, R., G.L. GODAERT, J.W. JACOBS, et al. 1996. Diminished autonomie nervous system responsiveness in rheumatoid arthritis of recent onset. J. Rheumatol. 23: 258-264.
64. MILLER, L.E., H.P. JUSTEN, J. SCHOLMERICH & R.H. STRAUB. 2000. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J. 14: 2097-2107.
65. JOE, B., M.M. GRIFFITHS, E.F. REMMERS & R.L. WILDER. 1999. Animal models of rheumatoid arthritis and related inflammation. Curr. Rheumatol. Rep. 1: 139-148.
66. SUN, B., S.H. SUN, C.C. CHAN & R.R. CASPI. 2000. Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp. Eye Res. 70: 493-502.
67. SAKAMOTO, S., A. FUKUSHIMA, A. OZAKI, et al. 2001. Mechanism for maintenance of dominant T helper 1 immune responses in Lewis rats. Microbiol. Immunol. 45:373-381.
68. BUYON, J.P. 1998. The effects of pregnancy on autoimmune diseases. J. Leukoc. Biol. 63: 281-287.
69. BUYON, J.P., J.L. NELSON & M.D. LOCKSHIN. 1996. The effects of pregnancy on autoimmune diseases. Clin. Immunol. Immunopathol. 78: 99-104.
70. CONFAVREUX, C., M. HUTCHINSON, M.M. HOURS, et al. 1998. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N. Engl. J. Med. 339: 285-291.
71. GRIFFITHS, M.M., J. WANG, B. JOE, et al. 2000. Identification of four new quantitative trait loci regulating arthritis severity and one new quantitative trait locus regulating autoantibody production in rats with collagen-induced arthritis. Arthritis Rheum. 43: 1278-1289.
72. MARZI, M., A. VIGANO, D. TRABATTONI, et al. 1996. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin. Exp. Immunol. 106: 127-133.
73. CADET, P., P.L. RADY, S.K. TYRING, et al. 1995. Interleukin-10 messenger ribonucleic acid in human placenta: implications of a role for interleukin-10 in fetal allograft protection. Am. J. Obstet. Gynecol. 173: 25-29.
74. GREIG, P.C., W.N. HERBERT, B.L. ROBINETTE & L.A. TEOT. 1995. Amniotic fluid interleukin-10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection. Am. J. Obstet. Gynecol. 173: 1223-1227.
75. ELENKOV, I.J., R.L. WILDER, V.K. BAKALOV, et al. 2001. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab. 86: 4933-4938.
76. ELENKOV, I.J., J. HOFFMAN & R.L. WILDER. 1997. Does differential neuroendocrine control of cytokine production govern the expression of autoimmune diseases in pregnancy and the postpartum period? Mol. Med. Today 3: 379-383.
77. KRONFOL, Z. & D.G. REMICK. 2000. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 157: 683-694.
78. CORCOS, M., O. GUILBAUD, L. HJALMARSSON, et al. 2002. Cytokines and depression: an analogic approach. Biomed. Pharmacother. 56: 105-110.
79. WICHERS, M. & M. MAES. 2002. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 5: 375-388.
80. WONG, M.L., M.A. KLING, P.J. MUNSON, et al. 2000. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. USA 97: 325-330.
81. GOLD, P.W. & G.P. CHROUSOS. 1999. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc. Assoc. Am. Physicians 111: 22-34.
82. GOLD, P.W. & G.P. CHROUSOS. 2002. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7: 254-275.
83. GREAVES, D.R. & K.M. CHANNON. 2002. Inflammation and immune responses in atherosclerosis. Trends Immunol. 23: 535-541.